<DOC>
	<DOC>NCT00695019</DOC>
	<brief_summary>The purpose of this study is to determine whether lozenges of interferon-alpha that are dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who had a complete virologic response after receiving a combination of injected interferon-alpha and oral ribavirin.</brief_summary>
	<brief_title>Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV genotype 1b Will be completing pegylated IFNalpha and ribavirin therapy within 4 weeks Serum HCV RNA negative within 4 weeks of study entry ChildPugh score of B or C Decompensated liver function History of malignancy within past 5 years Other causes of liver disease besides HCV infection Uncontrolled diabetes or hypertension Unwilling to use two forms of birth control during study treatment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Prevention of Relapse</keyword>
	<keyword>HCV genotype 1b</keyword>
	<keyword>Recurrence</keyword>
</DOC>